Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
四川科倫博泰生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 6990)

INSIDE INFORMATION
COMPLETION OF THE H SHARE FULL CIRCULATION BY THE COMPANY

This announcement is made by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "**Company**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements of the Company dated September 19, 2025, March 27, 2026 and April 8, 2026 (the "**Announcements**") in relation to the proposed implementation of the H Share Full Circulation of up to 3,572,088 domestic shares of the Company ("**Domestic Shares**") and 4,642,190 unlisted foreign shares of the Company ("**Unlisted Foreign Shares**"). Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Announcements.

COMPLETION OF THE H SHARE FULL CIRCULATION

The Board is pleased to announce that the conversion of an aggregate of 8,214,278 Domestic Shares and Unlisted Foreign Shares was completed on April 17, 2026 and the listing of the Converted H Shares on the Stock Exchange will commence at 9:00 a.m. on April 20, 2026.

SHARE CAPITAL UPON COMPLETION OF THE CONVERSION AND LISTING

The Conversion and Listing involved a total of three participating shareholders holding an aggregate of 8,214,278 Domestic Shares and Unlisted Foreign Shares, which represents approximately 3.52% of the total share capital of the Company upon completion of the Conversion and Listing, details of which are set out below:

Participating Shareholder	**Number of Converted H Shares**	**Approximate percentage of the Company's total share capital upon completion of the Conversion and Listing**
Holders of Domestic Shares and Unlisted Foreign Shares:		
Wealthy Linkage Limited	3,633,914	1.56%
Future Industry Investment Fund Phase II (Limited Partnership) (先進製造產業投資基金二期(有限合夥))	3,572,088	1.53%
Leyue Capital Limited	1,008,276	0.43%
Total	**8,214,278**	**3.52%**

The share capital structure of the Company immediately before and upon completion of the Conversion and Listing is as follows:

Description of shares	**Immediately before completion of the Conversion and Listing**		**Upon completion of the Conversion and Listing**	
	Number of shares	*Approximate percentage of the Company's total share capital*	*Number of shares*	*Approximate percentage of the Company's total share capital*
Domestic Shares	65,773,800	28.21%	62,201,712	26.68%
Unlisted Foreign Shares	4,642,190	1.99%	0	0%
H Shares	162,769,979	69.80%	170,984,257	73.32%
Total	**233,185,969**	**100.00%**	**233,185,969**	**100.00%**

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
LIU Gexin
Chairman of the Board and Non-executive Director

Hong Kong, April 17, 2026

As at the date of this announcement, the Board comprises Mr. LIU Gexin as the chairman of the Board and non-executive Director, Dr. GE Junyou as executive Director, Mr. LIU Sichuan, Mr. LAI Degui, Mr. FENG Hao, Ms. LIAO Yihong and Mr. ZENG Xuebo as non-executive Directors, and Dr. ZHENG Qiang, Dr. TU Wenwei, Dr. JIN Jinping and Dr. LI Yuedong as independent non-executive Directors.